Literature DB >> 23660698

Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis.

A Van Rie1, L Page-Shipp, K Mellet, L Scott, M Mkhwnazi, E Jong, T Omar, N Beylis, W Stevens, I Sanne, C N Menezes.   

Abstract

Xpert MTB/RIF (Xpert) is recommended for human immunodeficiency virus (HIV)-associated pulmonary tuberculosis but not extrapulmonary tuberculosis. We assessed the performance of Xpert for HIV-associated lymph node tuberculosis (LNTB), the most common type of extrapulmonary tuberculosis. Among HIV-infected adults suspected of LNTB presenting for fine needle aspirate (FNA) at a South African hospital, we assessed the diagnostic accuracy of Xpert using either FNA culture or a composite of microscopy, culture, and cytology as the reference standard, and evaluated the impact of different diagnostics on patient management. Among 344 adults with valid FNA culture and Xpert results, 84 (24 %) were positive on microscopy, 149 (43 %) on culture, 152 (53 %) on Xpert, and 181 (57 %) had a cytology result suggestive of tuberculosis. Using liquid culture as the reference standard, the specificity of a single Xpert was suboptimal (88.2 %) but the sensitivity was high [93.3 %, 95 % confidence interval (CI) 87.6-96.6] and increased with decreasing CD4 count (from 87.0 % for CD4 >250 to 98.6 % for CD4 <100 cells/mm(3)). Using a composite reference standard reduced the sensitivity to 79.2 % but increased the specificity to 98.6 %. All Xpert-positive patients initiated treatment within one day, compared to 70 % of culture-positive but Xpert-negative and 13 % of culture- and Xpert-negative but cytology-positive patients. Xpert is accurate and effective and could be endorsed as the initial diagnostic for HIV-associated LNTB.

Entities:  

Mesh:

Year:  2013        PMID: 23660698     DOI: 10.1007/s10096-013-1890-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  19 in total

1.  GeneXpert® MTB/RIF for rapid detection of Mycobacterium tuberculosis in pulmonary and extra-pulmonary samples.

Authors:  Shumaila N M Hanif; Hana S Eldeen; Suhail Ahmad; Eiman Mokaddas
Journal:  Int J Tuberc Lung Dis       Date:  2011-09       Impact factor: 2.373

2.  Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens.

Authors:  Sylvie Armand; Pascale Vanhuls; Guy Delcroix; René Courcol; Nadine Lemaître
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

3.  Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?

Authors:  Viral Vadwai; Catharina Boehme; Pamela Nabeta; Anjali Shetty; David Alland; Camilla Rodrigues
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

4.  Fine-needle aspiration biopsy of patients with acquired immunodeficiency syndrome (AIDS): experience in an outpatient clinic.

Authors:  K Bottles; L W McPhaul; P Volberding
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

5.  Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis.

Authors:  Enrico Tortoli; Cristina Russo; Claudio Piersimoni; Ester Mazzola; Paola Dal Monte; Michela Pascarella; Emanuele Borroni; Alessandra Mondo; Federica Piana; Claudio Scarparo; Luana Coltella; Giulia Lombardi; Daniela M Cirillo
Journal:  Eur Respir J       Date:  2012-01-12       Impact factor: 16.671

Review 6.  Extrapulmonary tuberculosis.

Authors:  S K Sharma; A Mohan
Journal:  Indian J Med Res       Date:  2004-10       Impact factor: 2.375

7.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

8.  Rapid and efficient detection of Mycobacterium tuberculosis in respiratory and non-respiratory samples.

Authors:  B Malbruny; G Le Marrec; K Courageux; R Leclercq; V Cattoir
Journal:  Int J Tuberc Lung Dis       Date:  2011-04       Impact factor: 2.373

Review 9.  Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  11 in total

Review 1.  Update on opportunistic infections in the era of effective antiretroviral therapy.

Authors:  Brian C Zanoni; Rajesh T Gandhi
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

Review 2.  Economic challenges associated with tuberculosis diagnostic development.

Authors:  Colleen F Hanrahan; Maunank Shah
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2014-04-28       Impact factor: 2.217

3.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

Review 4.  Diagnosis of opportunistic infections: HIV co-infections - tuberculosis.

Authors:  Lesley Scott; Pedro da Silva; Catharina C Boehme; Wendy Stevens; Christopher M Gilpin
Journal:  Curr Opin HIV AIDS       Date:  2017-03       Impact factor: 4.283

Review 5.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

6.  Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: establishing a laboratory testing algorithm for South Africa.

Authors:  Lesley Erica Scott; Natalie Beylis; Mark Nicol; Gloria Nkuna; Sebaka Molapo; Leigh Berrie; Adriano Duse; Wendy Susan Stevens
Journal:  J Clin Microbiol       Date:  2014-03-12       Impact factor: 5.948

Review 7.  Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review.

Authors:  Laura Maynard-Smith; Natasha Larke; Jurgens A Peters; Stephen D Lawn
Journal:  BMC Infect Dis       Date:  2014-12-31       Impact factor: 3.090

8.  Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies.

Authors:  Stephen D Lawn; Keertan Dheda; Andrew D Kerkhoff; Jonathan G Peter; Susan Dorman; Catharina C Boehme; Mark P Nicol
Journal:  BMC Infect Dis       Date:  2013-09-03       Impact factor: 3.090

9.  Epidemiology and diagnosis of tuberculous lymphadenitis in a tuberculosis low-burden country.

Authors:  Fernando Salvador; Ibai Los-Arcos; Adrián Sánchez-Montalvá; Teresa Tórtola; Adrian Curran; Ana Villar; Nuria Saborit; Josep Castellví; Israel Molina
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

10.  Evaluation of Xpert MTB/RIF for the Diagnosis of Lymphatic Tuberculosis.

Authors:  Hou-He Li; Zhi-Jian He; Jia-Qi Liang; Gui-Lin Li; Tian-Ao Xie; Ye-Ling Liu; Zhong-Wei Li; Xuan-Cheng Feng; Yong Xia; Xu-Guang Guo
Journal:  Biomed Res Int       Date:  2020-06-28       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.